Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
SPRY Stock Chart & Stats
$9.93
-$0.02(-0.18%)
At close: 4:00 PM EST
$9.93
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$6.66 - $18.90
Previous CloseN/A
Volume456.05K
Average Volume (3M)2.11M
Market Cap
$981.57M
Enterprise Value$802.57M
Total Cash (Recent Filing)$288.21M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Mar 19, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding98,848,610
10 Day Avg. Volume1,773,142
30 Day Avg. Volume2,108,783
Financial Highlights & Ratios
PEG Ratio-1.12
Price to Book (P/B)3.98
Price to Sales (P/S)11.47
P/FCF Ratio78.76
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue5.62
Enterprise Value/Gross Profit6.60
Enterprise Value/Ebitda-9.66
Forecast
1Y Price Target
$32.50Price Target Upside227.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$81.20M
Bulls Say, Bears Say
Bulls Say
Global ExpansionFuture regulatory approval in other geographies is expected over the coming quarters, which bodes well for the company's global expansion.
Market ExpansionNeffy approval in Japan expands the geographic reach of the product, which is already available in the U.S. and Germany and has recently received approval in the U.K.
Revenue GrowthARS reported total revenue of $32.5 million, including $31.3 million in U.S. neffy sales, which was ahead of expectations.
Bears Say
Prescription ChallengesManagement noted that it had underappreciated how overwhelmed by patient volumes practices would be during these peak weeks, which makes doctors less willing to prescribe a new treatment.
Program ImpactEnding the GoodRx program has been a headwind for weekly script numbers that have underwhelmed investors in recent weeks; however, this should have minimal impact on revenue.
Stock PerformanceThe weakness in shares of ARS in recent weeks, down over 40% since its highs in July, is considered unwarranted despite facing some headwinds.
ARS Pharmaceuticals News
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $6.66 and its highest was $18.90 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
ARS Pharmaceuticals’s market cap is $981.57M.
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is Mar 19, 2026 which is in 100 days.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.454 by -$0.066.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Undervalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -0.43.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 98,848,610 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.454. Following the earnings report the stock price went up 0.339%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Currently, no hedge funds are holding shares in SPRY
ARS Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.50 (227.29% Upside)
$32.50 (227.29% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.07%
12-Months-Change
Fundamentals
Return on Equity
-45.92%
Trailing 12-Months
Asset Growth
71.32%
Trailing 12-Months
Company Description
ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
SPRY Company Deck
SPRY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant revenue growth and strategic initiatives like the 'Get Nephi On Us' program and global expansion. However, challenges such as temporary pauses in market share growth, data inaccuracies, and expected Q4 sales decline were noted.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$32.50
▲(227.29% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
60.67% Insiders
9.96% Mutual Funds
8.30% Other Institutional Investors
12.57% Public Companies and
Individual Investors